Screener
GRAIL, Inc. GRAL Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$44.7MBeat by $2.3M
EPS-$2.56Beat by $0.10
Revenue estimate$42.4M
EPS estimate-$2.66
“GRAIL continues to execute across our clinical and commercial priorities. We presented detailed performance, safety, and clinical utility results from the NHS-Galleri and PATHFINDER 2 studies at the 2026 American Society of Clinical Oncology Annual Meeting, further establishing Galleri as the only MCED with extensive clinical validation from interventional studies in the screening population. We also expanded access through new and existing partnerships. Following our PMA submission earlier this year, we anticipate an FDA advisory committee in the fall.”
Next report
Nov 11, 2026 (in 2 months)Revenue estimate$44.3M
EPS estimate-$2.51
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did GRAIL, Inc. report Q2 2026 earnings?
- GRAIL, Inc. (GRAL) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were GRAIL, Inc.'s Q2 2026 revenue and EPS?
- GRAIL, Inc. reported revenue of $44.7M and eps of $-2.56 for Q2 2026.
- Did GRAIL, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $42.4M by $2.3M. EPS beat the consensus estimate of $-2.66 by $0.10.
- How did GRAIL, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 25.7% from $35.5M a year earlier and eps grew 19.5% from $-3.18.
- Where can I find GRAIL, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-053341) and the 10-Q periodic report (0001628280-26-054307) directly on SEC EDGAR. The filing index links above go to sec.gov.
